Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 29, Issue 2, 2016, Pages 179-195

  Pai, Rohan V ^a   Jain, Rajesh R ^a   Bannalikar, Anilkumar S ^b   Menon, Mala D ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b BOMBAY VETERINARY COLLEGE   (India)

Author keywords

Andersen Cascade Impactor (ACI); chitosan microparticles; Dry powder inhaler; Macrophage uptake

Indexed keywords

CHITOSAN MICROSPHERE; LACTOSE PERMEASE; NANOCARRIER; RIFABUTIN; RIFAMPICIN; UNCLASSIFIED DRUG; AEROSOL; CHITOSAN; DELAYED RELEASE FORMULATION; DRUG CARRIER; LACTOSE; POWDER; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG UPTAKE; DRY POWDER INHALER; GELATION; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; LUNG FLUID; LUNG TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; RAT; SPRAGUE DAWLEY RAT; SPRAY DRYING; SUSTAINED DRUG RELEASE; AEROSOL; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG STABILITY; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; KINETICS; LUNG; MACROPHAGE; METABOLISM; POWDER; SOLUBILITY; SURFACE PROPERTY; U-937 CELL LINE;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRY POWDER INHALERS; FEMALE; HUMANS; KINETICS; LACTOSE; LUNG; MACROPHAGES; PARTICLE SIZE; POWDERS; RATS, SPRAGUE-DAWLEY; RIFABUTIN; RIFAMPIN; SOLUBILITY; SURFACE PROPERTIES; U937 CELLS;

EID: 84964757871     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1187     Document Type: Article

References (50)

1. Du Toit LC, Pillay V, and Danckwerts MP: Tuberculosis chemotherapy: Current drug delivery approaches. Respir Res. 2006;7:118.
2. World Health O: Global tuberculosis report 2013.
3. Sahbazian B, and Weis SE: Treatment of active tuberculosis: Challenges and prospects. Clin Chest Med. 2005;26: 273-282.
4. Singh S, Mariappan T, Shankar R, Sarda N, and Singh B: A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixeddose combination (FDC) products, and the likely solutions to the problem. Int J Pharm. 2001;228:5-17.
5. de Souza MVN: Promising drugs against tuberculosis. Drug Discov. 2006;1:33-44.
6. Duncan K, and Barry III CE: Prospects for new antitubercular drugs. Curr Opin Microbiol. 2004;7:460-465.
7. Zhang Y, Post-Martens K, and Denkin S: New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discov Today. 2006;11:21-27.
8. Aristoff PA, Garcia GA, Kirchhoff PD, and Hollis Showalter H: Rifamycins-Obstacles and opportunities. Tuberculosis. 2010;90:94-118.
9. Ahmad Z, Pandey R, Sharma S, and Khuller G: Alginate nanoparticles as antituberculosis drug carriers: Formulation development, pharmacokinetics and therapeutic potential. J Chest Dis Allied Sci. 2006;48:171.
10. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, and Hickey AJ: Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res. 2001;18:1315-1319.
11. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, and Yeo Y: Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30:1947-1953.
12. Zhang J, Wu L, Chan HK, and Watanabe W: Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev. 2011;63:441-455.
13. Muttil P, Wang C, and Hickey AJ: Inhaled drug delivery for tuberculosis therapy. Pharm Res. 2009;26:2401-2416.
14. Pandey R, and Khuller G: Antitubercular inhaled therapy: Opportunities, progress and challenges. J Aantimicrob Chemother. 2005;55:430.
15. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, and Misra A: Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32:140-150.
16. Rinaudo M: Chitin and chitosan: Properties and applications. Prog Polym Sci. 2006;31:603-632.
17. Kean T and Thanou M: Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev. 2010;62:3-11.
18. Huang Y, Vieira A, Yeh M, and Chiang C: Pulmonary antiinflammatory effects of chitosan microparticles containing betamethasone. J Bioact Compat Polym. 2007;22:30-41.
19. Grenha A, Grainger CI, Dailey LA, Seijo B, Martin GP, Remuñán-López C, and Forbes B: Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci. 2007;31:73-84.
20. Aranaz I, Mengibar M, Harris R, Panos I, Miralles B, Acosta N, Galed G, and Heras A: Functional characterization of chitin and chitosan. Curr Chem Biol. 2009;3:203-230.
21. Ilium L: Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15:1326-1331.
22. Dodane V, and Vilivalam VD: Pharmaceutical applications of chitosan. Pharm Sci Technol To. 1998;1:246-253.
23. Lee C, Choi JS, Kim I, Oh KT, Lee ES, Park E-S, Lee KC, and Youn YS: Long-acting inhalable chitosan-coated poly (lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int J Nanomed. 2013;8:2975.
24. Ko J, Park H, Hwang S, Park J, and Lee J: Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm. 2002;249:165-174.
25. Forde S, Hynes MJ, and Jonson B: Dissolution of glass compositions containing no added lead in simulated lung fluid. Int J Hyg Envirl Heal. 2008;211:357-366.
26. Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, and Langer R: Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: The effect of 1, 2-dipalmitoylphosphatidylcholine. J Control Release. 1998;51:143-152.
27. Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma GI, Makino K, and Terada H: Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release. 2010;142:339-346.
28. Gupta K, and Jabrail FH: Glutaraldehyde cross-linked chitosan microspheres for controlled release of centchroman. Carbohydr Res. 2007;342:2244-2252.
29. Thompson CM, Subramaniam RP, and Grafström RC: Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. Toxicol Appl Pharmacol. 2008;233:355-359.
30. Agnihotri SA, Mallikarjuna NN, and Aminabhavi TM: Recent advances on chitosan-based micro-and nanoparticles in drug delivery. J Control Release. 2004;100:5-28.
31. Bhumkar DR, and Pokharkar VB: Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: A technical note. AAPS Pharm Sci Tech. 2006;7:138-143.
32. Yuan Y, Chesnutt B, Utturkar G, Haggard W, Yang Y, Ong J, and Bumgardner J: The effect of cross-linking of chitosan microspheres with genipin on protein release. Carbohydr Polym. 2007;68:561-567.
33. Dhawan S, Singla AK, and Sinha VR: Evaluation of mucoadhesive properties of chitosan microspheres prepared by different methods. AAPS Pharm Sci Tech. 2004;5:122-128.
34. Gupta K, and Jabrail FH: Effects of degree of deacetylation and cross-linking on physical characteristics, swelling and release behavior of chitosan microspheres. Carbohydr Polym. 2006;66:43-54.
35. Desai KGH, and Park HJ: Preparation and characterization of drug loaded chitosan-tripolyphosphate microspheres by spray drying. Drug Dev Res. 2005;64:114-128.
36. Nandiyanto ABD, and Okuyama K: Progress in developing spray-drying methods for the production of controlled morphology particles: From the nanometer to submicrometer size ranges. Adv Powder Technol. 2011;22:1-19.
37. Learoyd TP, Burrows JL, French E, and Seville PC: Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm. 2008;68:224-234.
38. Learoyd TP, Burrows JL, French E, and Seville PC: Modified release of beclometasone dipropionate from chitosan-based spray-dried respirable powders. Powder Technol. 2008;187:231-238.
39. Malcolmson RJ, and Embleton JK: Dry powder formulations for pulmonary delivery. Pharm Sci Technolo Today. 1998;1:394-398.
40. Walton D, and Mumford C: Spray dried products-Characterization of particle morphology. Chem Eng Res Des. 1999;77:21-38.
41. Cabral-Marques H, and Almeida R: Optimisation of spraydrying process variables for dry powder inhalation (DPI) formulations of corticosteroid/cyclodextrin inclusion complexes. Eur J Pharm Biopharm. 2009;73:121-129.
42. Stulzer HK, Tagliari MP, Parize AL, Silva MAS, and Laranjeira MCM: Evaluation of cross-linked chitosan microparticles containing acyclovir obtained by spray-drying. Mater Sci Eng: C. 2009;29:387-392.
43. Daniher DI, and Zhu J: Dry powder platform for pulmonary drug delivery. Particuology. 2008;6:225-238.
44. Sivadas N, O'Rourke D, Tobin A, Buckley V, Ramtoola Z, Kelly JG, Hickey AJ, and Cryan SA: A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int J Pharm. 2008;358:159-167.
45. Shoaib MH, Tazeen J, Merchant HA, and Yousuf RI: Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC. Pak J Pharm Sci. 2006;19:119-124.
46. Hirota K, Hasegawa T, Hinata H, Ito F, Inagawa H, Kochi C, Soma GI, Makino K, and Terada H: Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Control Release. 2007;119:69-76.
47. Makino K, Nakajima T, Shikamura M, Ito F, Ando S, Kochi C, Inagawa H, Soma GI, and Terada H: Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: Effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf B: Biointerfaces. 2004;36:35-42.
48. Hasegawa T, Iijima K, Hirota K, Nakajima T, Makino K, and Terada H: Exact determination of phagocytic activity of alveolar macrophages toward polymer microspheres by elimination of those attached to the macrophage membrane. Colloids Surf B: Biointerfaces. 2008;63:209-216.
49. Barrow ELW, Winchester GA, Staas JK, Quenelle DC, and Barrow WW: Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosisinfected macrophages. Antimicrob Agents Chemother. 1998; 42:2682.
50. Onoshita T, Shimizu Y, Yamaya N, Miyazaki M, Yokoyama M, Fujiwara N, Nakajima T, Makino K, Terada H, and Haga M: The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf B: Biointerfaces. 2010;76:151-157.